V. Bockstal

发表

T. brucei Infection Reduces B Lymphopoiesis in Bone Marrow and Truncates Compensatory Splenic Lymphopoiesis through Transitional B-Cell Apoptosis

S. Magez, S. Black, M. Radwanska, 2011, PLoS pathogens.

A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus.

F. Crauste, L. Solforosi, M. Prague, 2020, Journal of theoretical biology.

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study

V. Bockstal, Benoît Callendret, Auguste Gaddah, 2020, The Journal of infectious diseases.

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

S. Lees, D. Watson-Jones, B. Lowe, 2021, The Lancet. Infectious diseases.

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya

O. Anzala, V. Bockstal, M. Douoguih, 2019, The Journal of infectious diseases.

Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation

L. Solforosi, M. Prague, Irene Balelli, 2019, Journal of Virology.

A Critical Blimp-1-Dependent IL-10 Regulatory Pathway in T Cells Protects From a Lethal Pro-inflammatory Cytokine Storm During Acute Experimental Trypanosoma brucei Infection

L. Boon, E. Muraille, I. Humphreys, 2020, Frontiers in Immunology.

Durable natural killer cell responses after heterologous two-dose Ebola vaccination

Y. Lévy, E. Riley, R. Thiébaut, 2021, NPJ vaccines.

The central role of macrophages in trypanosomiasis-associated anemia: rationale for therapeutical approaches.

P. De Baetselier, M. Guilliams, S. Magez, 2010, Endocrine, metabolic & immune disorders drug targets.

Development of a pHrodo-Based Assay for the Assessment of In Vitro and In Vivo Erythrophagocytosis during Experimental Trypanosomosis

P. De Baetselier, S. Magez, B. Stijlemans, 2015, PLoS neglected tropical diseases.

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study

M. McElrath, S. D. De Rosa, M. Pau, 2022, PloS one.

Trypanosoma brucei Co-opts NK Cells to Kill Splenic B2 B Cells

S. Magez, S. Black, M. Radwanska, 2016, PLoS pathogens.

Acute Disruption of BoneMarrow B Lymphopoiesis and Apoptosis of Transitional andMarginal Zone B Cells in the Spleen following a Blood-Stage Plasmodium chabaudi Infection inMice

V. Bockstal, N. Geurts, StefanMagez, 2014 .

Acute Disruption of Bone Marrow B Lymphopoiesis and Apoptosis of Transitional and Marginal Zone B Cells in the Spleen following a Blood-Stage Plasmodium chabaudi Infection in Mice

S. Magez, V. Bockstal, N. Geurts, 2011, Journal of parasitology research.

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.

Y. Lévy, A. Pollard, J. Lelièvre, 2020, The Lancet. Infectious diseases.

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

H. Schuitemaker, D. Heerwegh, R. Roozendaal, 2022, npj Vaccines.

Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine

E. Wimmer, H. Schuitemaker, J. Cello, 2016, PLoS pathogens.

Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses

A. Pollard, E. Riley, M. Snape, 2020, The Journal of clinical investigation.

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

S. Lees, D. Watson-Jones, M. Belson, 2020, Trials.

NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans

Y. Lévy, O. Anzala, S. Sirima, 2022, Vaccines.

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

M. McElrath, O. Anzala, D. Heerwegh, 2022, PLoS medicine.

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen

V. Bockstal, Auguste Gaddah, M. Douoguih, 2021, npj Vaccines.

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

M. McElrath, O. Anzala, D. Heerwegh, 2021, PLoS medicine.

Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children

D. Watson-Jones, Pauline Akoo, D. Ishola, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania

S. Kapiga, D. Watson-Jones, P. Kaleebu, 2019, The Journal of infectious diseases.

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

S. Lees, D. Watson-Jones, B. Lowe, 2021, The Lancet. Infectious diseases.

Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination

A. Pollard, E. Riley, M. Snape, 2019, The Journal of infectious diseases.

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

H. Schuitemaker, Yvonne Wollmann, R. Roozendaal, 2020, npj Vaccines.

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

H. Schuitemaker, Yvonne Wollmann, R. Roozendaal, 2020, NPJ vaccines.

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike

B. Lambrecht, S. Marqusee, N. Callewaert, 2023, bioRxiv.

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen

V. Bockstal, Auguste Gaddah, M. Douoguih, 2021, NPJ vaccines.

Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen

H. Tinto, I. Valéa, R. Thiébaut, 2023, medRxiv.

Induction and regulation of Trypanosoma brucei VSG-specific antibody responses

V. Bockstal, P. Guirnalda, D. Frenkel, 2009, Parasitology.

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya

O. Anzala, V. Bockstal, M. Douoguih, 2019, The Journal of infectious diseases.

Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

M. Prague, V. Bockstal, M. Douoguih, 2023, NPJ vaccines.

Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial

L. Jagodzinski, M. Robb, M. Eller, 2024, Vaccines.

Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen

H. Tinto, I. Valéa, C. Lacabaratz, 2024, PLoS neglected tropical diseases.